The intersection of machine learning and biology is the future, and we want to be one of the first companies really helping push that forward. – CTech

It is not often when an entrepreneur with an idea to improve our lives can literally improve the biology of our bodies, but that is exactly what Luis Voloch and his co-founder Noam Solomon at Immunai are doing. Combining machine learning and biology, they are working to no and reprogram our immune systems by applying knowledge about certain cancers, for example, to other forms of cancer. The company currently works with various pharmaceutical companies to help them develop, improve, and combine their drugs, but Voloch has goals of helping people understand their immune systems better beyond cancer as well, and onto fighting autoimmune and age-related diseases as well. To reach their goals, they have hired the best and the brightest they can find in fields such as software, computational biology, and immunology. Other crucial characteristics for Immunais hires are that they are very curious about the other disciplines and want to learn and work together.

Click Here For More 20MinuteLeaders

Michael Matias, Forbes 30 Under 30, is the author of Age is Only an Int: Lessons I Learned as a Young Entrepreneur. He studies Artificial Intelligence at Stanford University, while working as a software engineer at Hippo Insurance and as a Senior Associate at J-Ventures. Matias previously served as an officer in the 8200 unit. 20MinuteLeaders is a tech entrepreneurship interview series featuring one-on-one interviews with fascinating founders, innovators and thought leaders sharing their journeys and experiences.

Contributing editors: Michael Matias, Amanda Katz

Read this article:
The intersection of machine learning and biology is the future, and we want to be one of the first companies really helping push that forward. - CTech

Related Posts

Comments are closed.